Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 4, 2008

Jiangsu Aosaikang Pharmaceutical Negotiates Chinese Rights to Access Pharma’s Phase II Cancer Drug

  • Jiangsu Aosaikang Pharmaceutical (ASK) signed on to manufacture, develop, and commercialize Access Pharmaceuticals’ anticancer agent for the Greater China Region. ProLindac™ is currently in Phase II studies and is active in a wide variety of solid tumors, according to the firms. The compound is a platinum prodrug.

    The Greater China region includes China, Hong Kong, Macau, and Taiwan. ASK will pay Access an upfront fee and subsequent milestone payments along with a double-digit royalty upon commercialization of ProLindac. In addition, ASK has committed to fund and execute two Phase II trials in colorectal cancer and another trial with an as yet undetermined focus. The companies believe that these Phase II studies would cost up to $20 million if conducted in the U.S. or Europe.

    ASK has also agreed to become a second source for the manufacturing of ProLindac. In addition, the company will be responsible for obtaining the necessary regulatory approvals for ProLindac.

    “ProLindac is a synergistic product to our current product portfolio and represents a significant innovation in the area of platinum-based cytotoxic agents,” says Qingcai Chen, Ph.D., president and chairman of ASK.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »